Literature DB >> 21816709

Mobility and safety in the multiple myeloma survivor: survivorship care plan of the International Myeloma Foundation Nurse Leadership Board.

Sandra I Rome1, Bonnie S Jenkins, Kathryn E Lilleby.   

Abstract

As in many other cancers, survivorship of multiple myeloma involves handling treatment, recovery from therapeutic interventions, the effects of the disease, and ongoing therapies. Although mobility challenges vary among survivors of multiple myeloma, these patients have an increased risk of impaired mobility because of side effects of therapy and the pathology of the disease, as well as other factors (e.g., increasing age). Health maintenance increasingly is becoming a part of the cancer control continuum, and nurses have the opportunity to help survivors of multiple myeloma optimize their functional mobility and safety, thereby preserving quality of life. The purpose of these practice recommendations is to provide the healthcare professional with information on mobility, fall risk, and planned activity as an integral part of the plan of care for patients with multiple myeloma. Tools for nurses and physicians for assessing and evaluating the newly diagnosed patient, the patient undergoing treatment, and the long-term survivor of multiple myeloma will be provided.

Entities:  

Mesh:

Year:  2011        PMID: 21816709     DOI: 10.1188/11.S1.CJON.41-52

Source DB:  PubMed          Journal:  Clin J Oncol Nurs        ISSN: 1092-1095            Impact factor:   1.027


  2 in total

1.  Maintaining bone health in patients with multiple myeloma: survivorship care plan of the International Myeloma Foundation Nurse Leadership Board.

Authors:  Teresa S Miceli; Kathleen Colson; Beth M Faiman; Kena Miller; Joseph D Tariman
Journal:  Clin J Oncol Nurs       Date:  2011-08       Impact factor: 1.027

2.  Perceived benefits and barriers to exercise for recently treated patients with multiple myeloma: a qualitative study.

Authors:  Melinda J Craike; Kaye Hose; Kerry S Courneya; Simon J Harrison; Patricia M Livingston
Journal:  BMC Cancer       Date:  2013-07-01       Impact factor: 4.430

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.